Recent Updates
Recently added Catalysts
GILD Positive Sentiment

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Tuesday, September 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Gilead Sciences has partnered with the Pan American Health Organization (PAHO) to enhance access to lenacapavir, a long-acting HIV prevention treatment, across Latin America and the Caribbean. This agreement aims to utilize PAHO's Regional Revolving Funds to create a coordinated pathway for distributing the medication. The initiative supports local efforts to combat HIV through pre-exposure prophylaxis (PrEP).

Market Sentiment Analysis

POSITIVE FACTORS

  • New partnership aims to improve HIV prevention access.
  • Lenacapavir will be available as a twice-yearly treatment.
  • Supports country-led efforts in Latin America and the Caribbean.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
Lenacapavir
Phase 3 · HIV Infections

Full Press Release Details

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led effor

Frequently Asked Questions

What is lenacapavir used for?

Lenacapavir is used for HIV prevention as pre-exposure prophylaxis (PrEP).

Who is partnering with Gilead for this initiative?

Gilead is partnering with the Pan American Health Organization (PAHO).

What regions will benefit from this partnership?

The partnership aims to benefit all PAHO Member States in Latin America and the Caribbean.

How will access to lenacapavir be expanded?

Access will be expanded through PAHO's Regional Revolving Funds.

ShareAdd on Google
Tags: GILD Viatris Investor Conferences Healthcare Gilead PAHO lenacapavir HIV prevention Latin America
Last updated: Sep 15, 2026

Biotech snapshot

Cash runway
$3179M liquidity · $0M/mo burn
Low dilution risk
Lead asset
LenacapavirPhase 3
HIV Infections →

Catalyst track record

+24%
best trade around GILD's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for GILD.

See every catalyst's timing & PoA →